We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Waters Expands Proteomics Reach With MOBILion Systems Acquisition
Read MoreHide Full Article
Key Takeaways
Waters acquires MOBILion to expand in the $2B LCMS proteomics market, growing at a high single-digit rate.
MOBILion's SLIM technology is expected to enhance proteome coverage, sensitivity and throughput for Waters.
WAT aims to advance AI-driven research and future blood-based diagnostics through expanded capabilities.
Waters (WAT - Free Report) recently announced the acquisition of MOBILion Systems, Inc., a pioneer of SLIM high-resolution ion mobility separation technology, to expand its presence in the proteomics market. The acquisition combines MOBILion's advanced molecular separation capabilities with Waters' mass spectrometry portfolio, strengthening its ability to support complex protein analysis, biomarker discovery and AI-enabled research workflows. The move creates opportunities to extend proteomics discoveries into clinical applications over time.
The acquisition accelerates Waters' entry into the attractive proteomics market, where liquid chromatography-mass spectrometry (LCMS) proteomics represents a $2 billion total addressable market, growing at a high single-digit rate.
According to management, the acquisition strengthens Waters' position in proteomics by combining MOBILion's SLIM ion mobility separation technology with the speed, resolution and sensitivity of its mass spectrometry portfolio. This integration is expected to help researchers better understand complex biological processes, generate actionable insights and produce large-scale datasets to support AI-driven research and lab-in-the-loop workflows.
WAT Stock Trend Following the News
Year to date, the stock gained 20.5%, outperforming the industry’s 2.7% growth and the S&P 500’s 7.2% rise.
The acquisition strengthens Waters' competitive positioning in the growing proteomics market by broadening its technology portfolio and expanding its opportunities beyond traditional analytical workflows. Greater capabilities in protein analysis could help the company attract research institutions and pharmaceutical customers. The potential to translate research findings into clinical testing creates a longer-term growth opportunity, allowing Waters to participate in the expanding market for precision diagnostics and blood-based disease monitoring.
WAT currently has a market capitalization of $44.96 billion.
Image Source: Zacks Investment Research
More on the News
MOBILion's SLIM (Structures for Lossless Ion Manipulations) technology provides high-resolution ion mobility separation, distinguishing molecules based on size, shape and charge in milliseconds. Combined with Waters' Xevo MRT mass spectrometry platform, it is expected to improve proteome coverage, sensitivity and throughput in complex biological samples compared with LCMS alone. The acquisition also brings MOBILion's team and expertise in ion mobility technology to Waters.
The deal supports high-throughput proteomics research by enabling large-scale generation of high-quality data for AI foundation and frontier models. Waters will leverage AI Link, which integrates Anthropic's Model Context Protocol (MCP) into its waters_connect software. Its participation in Anthropic's Model Hardware Standard (MHS) research program will support lab-in-the-loop workflows. These allow AI agents to help design experiments and direct instrument operations.
Waters' Xevo TQ Absolute XR tandem quadrupole mass spectrometer could facilitate biomarker verification and validation in clinical trial cohorts. The waters_connect platform supports method transfer from discovery to development. Over time, Waters' installed base of mass spectrometers in clinical laboratories could support blood-based diagnostic testing, such as Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) monitoring. The companies did not disclose the financial terms of the acquisition.
Industry Prospects Favoring the Market
According to Grand View Research, the global proteomics market is estimated to reach $43.7 billion in 2026 and is projected to witness a CAGR of 12.2% through 2033.
Factors such as rising demand for precision medicine, increasing R&D activities, growing adoption of advanced mass spectrometry technologies and expanding applications of protein biomarkers in drug discovery and clinical diagnostics are driving market growth. Advancements in AI-enabled protein analysis and high-throughput research workflows are further supporting the market's expansion.
Other News
Waters recently launched AI-Powered Peak Integration for its Empower Software, automating chromatography data processing in regulated laboratories. The AI-powered capability is expected to reduce manual interventions by up to 95%, improve accuracy by 76% and lower user-to-user variability by 72%. Early access is expected in December 2026.
Waters also launched AI Link, integrating Anthropic’s Model Context Protocol into its waters_connect software to enable AI-driven laboratory workflows. The technology allows scientists to control instruments using AI agents, automate experiments and accelerate research and development, with workflows extending into regulated environments.
Some top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
View the Zacks #1 Rank List
Image: Shutterstock
Waters Expands Proteomics Reach With MOBILion Systems Acquisition
Key Takeaways
Waters (WAT - Free Report) recently announced the acquisition of MOBILion Systems, Inc., a pioneer of SLIM high-resolution ion mobility separation technology, to expand its presence in the proteomics market. The acquisition combines MOBILion's advanced molecular separation capabilities with Waters' mass spectrometry portfolio, strengthening its ability to support complex protein analysis, biomarker discovery and AI-enabled research workflows. The move creates opportunities to extend proteomics discoveries into clinical applications over time.
The acquisition accelerates Waters' entry into the attractive proteomics market, where liquid chromatography-mass spectrometry (LCMS) proteomics represents a $2 billion total addressable market, growing at a high single-digit rate.
According to management, the acquisition strengthens Waters' position in proteomics by combining MOBILion's SLIM ion mobility separation technology with the speed, resolution and sensitivity of its mass spectrometry portfolio. This integration is expected to help researchers better understand complex biological processes, generate actionable insights and produce large-scale datasets to support AI-driven research and lab-in-the-loop workflows.
WAT Stock Trend Following the News
Year to date, the stock gained 20.5%, outperforming the industry’s 2.7% growth and the S&P 500’s 7.2% rise.
The acquisition strengthens Waters' competitive positioning in the growing proteomics market by broadening its technology portfolio and expanding its opportunities beyond traditional analytical workflows. Greater capabilities in protein analysis could help the company attract research institutions and pharmaceutical customers. The potential to translate research findings into clinical testing creates a longer-term growth opportunity, allowing Waters to participate in the expanding market for precision diagnostics and blood-based disease monitoring.
WAT currently has a market capitalization of $44.96 billion.
Image Source: Zacks Investment Research
More on the News
MOBILion's SLIM (Structures for Lossless Ion Manipulations) technology provides high-resolution ion mobility separation, distinguishing molecules based on size, shape and charge in milliseconds. Combined with Waters' Xevo MRT mass spectrometry platform, it is expected to improve proteome coverage, sensitivity and throughput in complex biological samples compared with LCMS alone. The acquisition also brings MOBILion's team and expertise in ion mobility technology to Waters.
The deal supports high-throughput proteomics research by enabling large-scale generation of high-quality data for AI foundation and frontier models. Waters will leverage AI Link, which integrates Anthropic's Model Context Protocol (MCP) into its waters_connect software. Its participation in Anthropic's Model Hardware Standard (MHS) research program will support lab-in-the-loop workflows. These allow AI agents to help design experiments and direct instrument operations.
Waters' Xevo TQ Absolute XR tandem quadrupole mass spectrometer could facilitate biomarker verification and validation in clinical trial cohorts. The waters_connect platform supports method transfer from discovery to development. Over time, Waters' installed base of mass spectrometers in clinical laboratories could support blood-based diagnostic testing, such as Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) monitoring. The companies did not disclose the financial terms of the acquisition.
Industry Prospects Favoring the Market
According to Grand View Research, the global proteomics market is estimated to reach $43.7 billion in 2026 and is projected to witness a CAGR of 12.2% through 2033.
Factors such as rising demand for precision medicine, increasing R&D activities, growing adoption of advanced mass spectrometry technologies and expanding applications of protein biomarkers in drug discovery and clinical diagnostics are driving market growth. Advancements in AI-enabled protein analysis and high-throughput research workflows are further supporting the market's expansion.
Other News
Waters recently launched AI-Powered Peak Integration for its Empower Software, automating chromatography data processing in regulated laboratories. The AI-powered capability is expected to reduce manual interventions by up to 95%, improve accuracy by 76% and lower user-to-user variability by 72%. Early access is expected in December 2026.
Waters also launched AI Link, integrating Anthropic’s Model Context Protocol into its waters_connect software to enable AI-driven laboratory workflows. The technology allows scientists to control instruments using AI agents, automate experiments and accelerate research and development, with workflows extending into regulated environments.
Waters Corporation Price
Waters Corporation price | Waters Corporation Quote
WAT’s Zacks Rank & Key Picks
Currently, Waters carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.